The Top 5 Biosimilar Articles for the Week of August 25

Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease

January 18th 2025

By Deana Ferreri, PhD

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimliar's FDA approval.

The Top 5 Biosimilar Articles for the Week of January 13

January 17th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 13, 2025.

Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas

January 16th 2025

By Skylar Jeremias

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.

Biosimilar Tocilizumab Cost-Effective for Treatment of Rheumatoid Arthritis in Spain

January 16th 2025

By Cameron Santoro

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid arthritis (RA) after experiencing improved outcomes.

Improving Biosimilar Access Through Global Regulatory Convergence

January 15th 2025

By Skylar Jeremias

Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.

Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab

January 14th 2025

By Skylar Jeremias

The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.

The Next Frontier: Oncology Biosimilars in 2025 and Beyond

January 13th 2025

By Prateek Yadav, MPTh, MBA

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.

Streamlining Biosimilar Access: How EHR Automation Transforms Patient Care

January 12th 2025

By Skylar Jeremias

Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals

January 11th 2025

By Skylar Jeremias

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.

The Top 5 Biosimilar Articles for the Week of January 6

January 10th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 6, 2025.